SALT LAKE CITY, June 12, 2018 (GLOBE NEWSWIRE) -- Nu-Med Plus, Inc. (OTCQB:NUMD), a medical device company which investigates and develops applications of Nitric Oxide technologies in the medical field, has selected Millennium Biosciences as their strategic partner for company quality and regulatory service.  Mr. Mike D’Amico who leads Millennium has been a successful, focused, quality-driven scientific leader with global strategic Quality systems and Regulatory experience within the scientific community.

Inhaled Nitric oxide(INO) is a medically essential gas that is presently used in Neonate Hypoxia therapy (inadequate oxygen level in newborns), COPD and other pulmonary problems and may have future applications for a variety of other diseases and medical complications that are currently being investigated.

“For the past 30+ years, Mr. D’Amico has been a successful professional in the Quality and Regulatory field in the capacities of quality project management and regulatory affairs. We are excited to have retained Millennium Biosciences as we aggressively step forward pursuing ISO 13485 training and certification for our company along with approvals for our products," commented Mr. Jeff Robins, President and CEO of Nu-Med-Plus.

About Nu-Med Plus, Inc.
Nu-Med Plus, Inc. is a medical device development company created to explore medical applications of newly developed technologies. The strategy is to focus on high growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of inhaled nitric oxide gas for therapeutic use. For more information please visit www.nu-medplus.com.

Forward-Looking Statements
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

Contact:
Jeff Robins/President 801-746-3570